Effect of moricizine hydrochloride in reducing chronic high-frequency ventricular arrhythmia: Results of a prospective, controlled trial

Effect of moricizine hydrochloride in reducing chronic high-frequency ventricular arrhythmia: Results of a prospective, controlled trial

The antiarrhythmic efficacy of moricizine HCI (Ethmozine ®), a new oral phenothiazine derivative, was evaluated in 20 patients with chronic high-fre-quency ventricular arrhythmia confirmed by multiple ambulatory electrocardiographic recordings. Comparison with 72 ± 24 hours (± standard de-viation) o...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology Vol. 53; no. 6; pp. 745 - 750
Main Authors: Singh, Steven N., DiBianco, Robert, Gottdiener, John S., Ginsberg, Rick, Fletcher, Ross D., Johnson, Wanda L., Cockrell, James C.
Format: Journal Article
Language:English
Published: United States Elsevier Inc 01-03-1984
Subjects:
Adult
Aged
Anti-Arrhythmia Agents - adverse effects
Anti-Arrhythmia Agents - therapeutic use
Arrhythmias, Cardiac - drug therapy
Chronic Disease
Clinical Trials as Topic
Echocardiography
Electrocardiography
Exercise Test
Heart - physiopathology
Humans
Male
Middle Aged
Moricizine
Phenothiazines - adverse effects
Phenothiazines - therapeutic use
Prospective Studies
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The antiarrhythmic efficacy of moricizine HCI (Ethmozine ®), a new oral phenothiazine derivative, was evaluated in 20 patients with chronic high-fre-quency ventricular arrhythmia confirmed by multiple ambulatory electrocardiographic recordings. Comparison with 72 ± 24 hours (± standard de-viation) of ambulatory recordings on moricizine treatment (average dose 295 ± 58 mg 3 times daily or 9.8 ± 1.0 mg/kg/day) was made. Maximal treadmill exercise provocation of arrhythmia and echocardiographic studies to detect effects on left ventricular function were also compared. The group had an average of 378 ± 97 ventricular premature beats (VPBs) per hour while receiving placebo, with a mean VPB grade of 3.4 ± 1.1 (modified Lown). When the patients received moricizine HCI, VPB frequency was reduced 53% (p < 0.01), to a mean VPB grade of 2.2 ± 1.4 (p < 0.05). Seventy percent of the patients (14 of 20) showed a reduction in VPB frequency that exceeded the maximal expected variation; in 3 the frequency did not change and in 3 it increased with moricizine HCI. Resting elec-trocardiographic changes consisted of modest prolongations of PR interval (0.03 second) and QRS duration (0.02 second); however, QT prolongation was not observed. Heart rate and blood pressure at rest and peak exercise, exercise-related arrhythmia, exercise durations and echocardiographic measures of left ventricular function were unchanged by mo-ricizine HCI compared with placebo. Side effects of morcizine HCI at these dosages were minimal (di-arrhea in 1 patient, dizziness in 1 and diaphoresis in 1 ), although 2 patients tested at higher dosages had sustained ventricular tachycardia that may have been related to moricizine HCI. Moricizine HCI was found to be an effective and unusually well tolerated antiarrhythmic agent when administered orally 3 times daily at dosages of approximately 10 mg/ kg/day.
ISSN:0002-9149
1879-1913
DOI:10.1016/0002-9149(84)90397-7